It is the prevailing wisdom among both the legal academy and the general public that the regulatory system is better able to ensure the safety of risky products than the tort system. In this article I argue that this is not always the case. Contrary to sharp criticisms of “regulation by litigation” propounded by leading academics such as Richard Epstein, Richard Reich, and Peter Shuck, tort litigation is sometimes the only way to encourage product safety, at least in settings where manufacturers conceal key information needed to evaluate product safety. Without this litigation, we might still be using products that we know now are exceedingly dangerous
Since the citadel of privity first crumbled for manufacturers of defective products decades ago, sta...
Comparing the experience of Vioxx and Celebrex leads Omri Ben-Shahar to think that stiff product lia...
We explain in this Article that the benefits of product liability may well be outweighed by its cost...
As consumers, we assume that the automobiles, pharmaceuticals, medical devices, and other products w...
The dispute over FDA regulatory preemption is familiar: Preemption advocates assert that products li...
This Article focuses on one emerging aspect of tort litigation against pharmaceutical manufacturers ...
While no one would dispute that safety is a desirable objective, it may not always be an absolute pr...
The author considers whether strict liability should be imposed for injuries caused by products that...
Society approaches health and safety risks in a piecemeal fashion. Regulators attempt to control the...
The plaintiffs\u27 daughter was four years old when they brought her in to the local medical clinic....
Many commentators argue that tort law is inappropriate for responding to the risks posed by emerging...
Professor Wertheimer has proposed that courts be allowed to hold producers strictly liable for produ...
Professor Green addresses the matter of the proper balance between the tort system and regulation in...
This Article examines the interaction between direct regulation of pharmaceuticals under the Federal...
The heart of the Article is an exploration of the possible role of common law tort liability in both...
Since the citadel of privity first crumbled for manufacturers of defective products decades ago, sta...
Comparing the experience of Vioxx and Celebrex leads Omri Ben-Shahar to think that stiff product lia...
We explain in this Article that the benefits of product liability may well be outweighed by its cost...
As consumers, we assume that the automobiles, pharmaceuticals, medical devices, and other products w...
The dispute over FDA regulatory preemption is familiar: Preemption advocates assert that products li...
This Article focuses on one emerging aspect of tort litigation against pharmaceutical manufacturers ...
While no one would dispute that safety is a desirable objective, it may not always be an absolute pr...
The author considers whether strict liability should be imposed for injuries caused by products that...
Society approaches health and safety risks in a piecemeal fashion. Regulators attempt to control the...
The plaintiffs\u27 daughter was four years old when they brought her in to the local medical clinic....
Many commentators argue that tort law is inappropriate for responding to the risks posed by emerging...
Professor Wertheimer has proposed that courts be allowed to hold producers strictly liable for produ...
Professor Green addresses the matter of the proper balance between the tort system and regulation in...
This Article examines the interaction between direct regulation of pharmaceuticals under the Federal...
The heart of the Article is an exploration of the possible role of common law tort liability in both...
Since the citadel of privity first crumbled for manufacturers of defective products decades ago, sta...
Comparing the experience of Vioxx and Celebrex leads Omri Ben-Shahar to think that stiff product lia...
We explain in this Article that the benefits of product liability may well be outweighed by its cost...